Clinical Trials Day 2026: ‘Research Rising’ Theme Reflected in Q1 Study Growth
Clinical Trials Day 2026 highlighted a 1.3% rise in global Phase I‑III trial initiations in Q1, with China accounting for one‑third of the new studies and posting a 6.5% year‑on‑year increase. Europe and the United States also accelerated, growing 9.8% and 12% respectively. While oncology still dominates trial pipelines, metabolic and immunology disease areas surged 47% and 43% between 2024 and 2025. Rising trial complexity is inflating costs, prompting firms to seek Chinese licensing partnerships to replenish pipelines.
QIAGEN and NVIDIA Partner on AI Drug Discovery
Qiagen’s Digital Insights division will embed NVIDIA’s accelerated computing and BioNeMo platform into its bioinformatics suite, creating a graph‑based AI environment for drug discovery. The integration is designed to streamline target identification, biomarker discovery, and multi‑omics hypothesis generation for pharma...
Tracy Beth Høeg Ousted From FDA in Wider Senior Leadership Shakeup
Tracy Beth Høeg was dismissed after just six months as acting head of the FDA’s Centre for Drug Evaluation and Research (CDER), marking the fifth leadership change at the unit since President Trump’s second term began. During her brief tenure, Høeg pushed...
Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF
Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by Japan’s Ministry of Health, Labour and Welfare for treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B inhibitor with antifibrotic and immunomodulatory properties to receive such...
The Ovarian Cancer Opportunity: Overcoming Complexity in Global Studies
Ovarian cancer affects over 21,000 U.S. women annually, with a 60% mortality rate. Recent FDA approvals—pembrolizumab + paclitaxel and relacorilant + nab‑paclitaxel—offer modest gains, while mirvetuximab targets the 25% of patients expressing folate‑receptor α. GlobalData reports 86 active Phase III trials and 28 in planning, reflecting...
ECO 2026: Indirect Comparison Favours Wegovy Pill over Foundayo
At the 33rd European Congress on Obesity, Novo Nordisk presented a post‑hoc indirect comparison of oral semaglutide (Wegovy pill) versus orforglipron (Foundayo). Using simulated treatment comparison and matching‑adjusted indirect methods, the analysis showed Wegovy achieved roughly 3 percentage‑points greater weight...
Arna Pharma and Slate Run Complete JV for New US Company
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture to create a U.S.-based specialty pharmaceutical company focused on branded products, 505(b)(2) medicines, and specialized generics. The partnership launched its first collaborative product, Aridol, and plans to add more...
Kyowa Kirin Secures FDA Approval for Crysvita Dosing Update
Kyowa Kirin has secured FDA approval to expand Crysvita’s dosing regimen for adults with X‑linked hypophosphataemia (XLH). The update allows a 0.5 mg/kg dose up to 90 mg every two weeks, with the option to increase to 1 mg/kg after four weeks if serum...
Regulatory Round-Up: A Month of Key FDA Approvals for Cancer Drugs
The FDA approved four oncology drugs in May 2026, marking a focused regulatory push in cancer therapeutics. Taiho Oncology received clearance for the oral Inqovi‑venetoclax regimen for elderly acute myeloid leukemia patients, while BeOne Medicines earned accelerated approval for Beqalzi...
Imfinzi Set to Become First Immunotherapy for Stomach Cancer Patients on NHS
AstraZeneca’s immunotherapy Imfinzi (durvalumab) has received NICE approval, becoming the first immunotherapy available on the UK NHS for patients with resectable gastric and gastro‑oesophageal junction cancers. The approval follows the Phase III MATTERHORN trial, which showed that adding Imfinzi to standard...
Pfizer Receives EC Approval for Hympavzi to Treat Haemophilia
Pfizer secured European Commission marketing authorisation for Hympavzi (marstacimab) to treat hemophilia A or B with inhibitors in patients aged 12 years and older weighing at least 35 kg. The once‑weekly subcutaneous therapy showed a 93% reduction in mean annualised bleeding rate versus on‑demand...
Pharma’s Manufacturing Reconfigurations Provide CDMOs with Expansion Opportunities
A wave of pharma‑to‑CDMO facility sales accelerated in early 2026, highlighted by Samsung Biologics acquiring GSK’s Rockville plant. The deal adds 60,000 L of drug‑substance capacity, giving Samsung its first U.S. manufacturing footprint and boosting its global capacity by roughly 8%....
BridgeBio’s Attruby Challenges Pfizer’s Vyndamax Legacy in Pivotal ATTR Trial
BridgeBio unveiled pivotal Phase III ATTRibute‑CM data for its FDA‑approved drug Attruby at the ESC 2026 Heart Failure congress. The study showed sustained wild‑type transthyretin levels, a 40% drop in outpatient worsening heart‑failure events, and a 34% reduction in cardiovascular hospitalisations...
FDA Locks Down Post-Approval Pregnancy Safety Data Framework
The FDA issued final guidance on post‑marketing safety data collection for drugs and biologics used in pregnancy. The framework details best practices for pregnancy registries, case‑control, electronic health record‑based and population‑level studies, stressing early enrollment and multi‑pronged recruitment. It requires...
Japan’s FY26 Price Revision Expands G1 Repricing and Drives Price Reduction
Japan’s FY26 National Health Insurance drug price revision took effect in April 2026, lowering average prices by 4.02% across about 15,800 products. The revision expands the G1 repricing rule to all off‑patent medicines and biologics with biosimilar competition, driving price...
AI-Guided Labs Are Approaching Full Autonomy
Ginkgo Bioworks is building fully autonomous biopharma labs that combine 70 robots, 90 lab devices and AI‑driven software in an 18,000‑square‑foot Boston facility. Scientists can submit dozens of unique protocols each day, which the system executes without human intervention. In...
Streamline Data Capture and Automate EHR-to-EDC Data Transfer
Paradigm Health introduced eSource Casebook, an EHR‑integrated platform that extracts both structured and unstructured clinical data, auto‑populates electronic case report forms, and streams the information directly to sponsor EDC systems. The tool tackles the industry‑wide surge in manual data entry,...
Podcast: Autonomous Labs Redefine the Role of Biopharma Researchers
Autonomous laboratories, integrating robotic hardware with AI-driven decision making, are emerging as a transformative force in biopharma R&D. In a GlobalData Media podcast, Frankie Fattorini interviewed Jason Kelly, CEO of Ginkgo Bioworks, who described how these labs can conduct experiments with unprecedented precision...
An Essential Framework to Navigating Technical Challenges in Contemporary OSD Development
Oral solid dosage (OSD) development faces mounting technical hurdles as biopharma pipelines become richer in poorly soluble compounds, with 70‑90% of new small‑molecule candidates classified as BCS Class II or IV. Early‑risk identification—through comprehensive physicochemical profiling, excipient compatibility testing, and Quality...
Citius Raises $36.5m for Lymphir Commercialisation
Citius Oncology announced up to $36.5 million in combined debt and equity financing to speed the commercial launch of Lymphir, its FDA‑approved therapy for relapsed or refractory cutaneous T‑cell lymphoma. The package includes a senior secured term loan of up to...
DDW 2026: Key Readouts From the Conference
Digestive Disease Week 2026 in Chicago showcased several pivotal GI‑focused readouts. AbbVie reported real‑world Skyrizi data showing steroid use fell from 34% to 7% after 52 weeks and 77% of Crohn’s patients reported improved quality of life. Johnson & Johnson’s...
MSD Concludes Terns Acquisition to Expand CML Pipeline
Merck (MSD) completed its $5.3 bn acquisition of Terns Pharmaceuticals, making the biotech a wholly‑owned subsidiary. The deal secures TERN‑701, an oral allosteric BCR‑ABL1 inhibitor that recently earned FDA breakthrough‑therapy designation for Philadelphia chromosome‑positive chronic myeloid leukaemia. MSD will record a...
Overcoming Material Constraints: Aseptic Filling Solutions for Rare or Expensive APIs
Aseptic fill‑finish lines can waste more than a liter of drug product per batch, translating to losses exceeding $1 million for high‑value APIs. The bulk of this loss occurs during sterile filtration and filling, where product remains trapped in vessels, tubing,...
Madrigal Outlays $1bn for Arrowhead’s siRNA MASH Asset
Madrigal Pharmaceuticals has secured global rights to Arrowhead Pharmaceuticals’ siRNA asset ARO‑PNPLA3 for treating metabolic dysfunction‑associated steatohepatitis (MASH) in a deal valued at up to $1 bn, including a $25 m upfront payment. The therapy, which silences the PNPLA3 gene, showed a...
The Cost of Inefficiencies in Clinical Trials
Clinical trials are hampered by fragmented technology, leading to roughly 45% higher costs compared with unified platforms. Integration fees, duplicate data entry, and managing multiple vendors add significant expense and delay timelines. Unified data‑management solutions such as CRScube claim 50‑60%...
How Saudi Arabia Is Developing as a Middle East Hub for Clinical Trials
Saudi Arabia is positioning itself as the Middle East’s primary hub for clinical trials, backed by robust state investment and the Vision 2030 Health Sector Transformation Programme. Healthcare spending is forecast to reach $61.05 million in 2026, while pharmaceutical sales are...
BMS Brings the Buzz Around Late-Stage Readouts Amid a So-So Q1
Bristol Myers Squibb’s Q1 earnings showed modest 1% revenue growth to $11.5 bn, beating forecasts, while its growth portfolio surged 9% to $6.2 bn. The company highlighted late‑stage readouts for milvexian, a next‑generation anticoagulant, and Cobenfy, a schizophrenia therapy, as potential blockbuster...
EU’s Joint Clinical Assessment System Still Finding Its Footing
The European Union’s Joint Clinical Assessment (JCA) system, launched in January 2025, saw its first activation with Ipsen’s Ojemda approval, initiating a 30‑day countdown for a centralized clinical report. Designed to replace duplicated health‑technology assessments across member states, the JCA currently...
Regeneron Q1 2026 Net Income Falls 10% to $727m
Regeneron reported GAAP net income of $727 million for Q1 2026, a 10% decline from the prior year, while non‑GAAP net income rose 12% to $1.04 billion. Total revenue jumped 19% to $3.6 billion, driven by an 8% increase in net product sales and...
The Strategic Investments Expanding CDMO Capabilities for HPAPIs and ADCs
Contract development and manufacturing organisations (CDMOs) are accelerating investments to meet soaring demand for highly potent active pharmaceutical ingredients (HPAPIs) and antibody‑drug conjugates (ADCs). The focus is on backward integration, high‑containment infrastructure, and advanced processing such as chromatography and lyophilisation...
Arcera and Fosun Sign MoU for Neuroscience Innovation
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding to create a long‑term strategic partnership focused on licensing, technology sharing, and neuroscience innovation. The deal taps Fosun’s research and manufacturing capabilities and Arcera’s access to international markets,...
Rocket to Sell PRV for $180m to Advance Gene Therapy Pipeline
Rocket Pharmaceuticals has agreed to sell its rare‑pediatric disease priority review voucher for $180 million after the FDA granted accelerated approval for its Kresladi gene therapy. The voucher, issued for addressing a rare paediatric condition, can be used to speed up...
Seaport and Hemab Target $180m IPOs as Biotech Listings Accumulate
Seaport Therapeutics and Hemab Therapeutics announced IPO pricing on the Nasdaq, each targeting roughly $180 million in net proceeds. Seaport will sell 11.8 million shares at $16‑$18, estimating $183.5 million at the midpoint, while Hemab will offer 11.7 million shares in the same range...
Early Detection of Bowel Cancer in the UK Represents Success of Screening Program
The UK’s bowel‑cancer screening programme, launched in 2006, is delivering measurable gains. NHS data show 7 million people screened in 2025, up from 4.7 million in 2015, and 70,000 cancers detected among 85 million tests. The rollout of home‑based faecal immunochemical kits and...
Pharma Meets AI Conference 2026: AI in Pharma Begins Delivering Measurable ROI
At the Pharma Meets AI conference in Barcelona, industry leaders highlighted that artificial intelligence is finally moving beyond pilot projects to deliver quantifiable returns in pharmaceutical commercial and field‑medical operations. Exeevo showcased its Ask‑Nova platform, which embeds AI into routine...
Pharma Meets AI Conference 2026: AI Governance Shifts to Embedded Practice
At the Pharma Meets AI conference in Barcelona, industry leaders announced a pivot from standalone AI policy frameworks to embedded governance models. Novartis presented an “integrated assurance” approach that fuses risk management, compliance, and internal controls directly into business processes....
ESCMID Global 2026: Pritelivir Excels in Immunocompromised Refractory HSV Patients
Aicuris presented Phase III data for its oral helicase‑primase inhibitor pritelivir at ESCMID Global 2026. In the PRIOH‑1 trial of 101 immunocompromised adults with acyclovir‑refractory HSV, pritelivir achieved significantly higher lesion‑healing rates than investigator‑chosen IV or topical therapies. The drug also...
MFN Changing the Rules of the Game for the Nordic Countries
GlobalData’s Price Intelligence analysis links the U.S. Most Favored Nation (MFN) policy to a 35% decline in pharmaceutical product launches across Europe within ten months of its introduction. In the Nordics, oncology drugs are priced roughly 5% below the European...
Novartis Secures Pair of Regulatory Wins for Skin Disease and Malaria Treatments
Novartis won two regulatory milestones: the European Commission approved its oral BTK inhibitor Rhapsido for adults with chronic spontaneous urticaria who have failed antihistamines, and the World Health Organization granted prequalification to Coartem Baby, an artemether‑lumefantrine formulation for infants weighing 2‑5 kg....
UK Biotech Could Be Bound for Recovery, BIA Report Reveals
UK biotech venture financing rebounded in Q1 2026, with total equity raised climbing 18% to £552 m ($746 m). Venture‑capital inflows also rose 17% to £516 m ($699 m), and 25 companies secured funding, up from 15 a year earlier. While public‑market activity stayed flat—no...
The Slow March of Clinical Biomarkers to Become Surrogate Endpoints
Clinicians are urging the FDA to recognize more clinical biomarkers as surrogate endpoints, hoping to accelerate drug approvals and reduce trial durations. Regulators remain cautious, approving only six biomarkers through the 2007 Biomarker Qualification Programme and often demanding definitive clinical...
AAN 2026: Tavapadon Post-Hoc Analysis Strengthens Its D1/D5 Agonist Pitch
At the 2026 American Academy of Neurology meeting, AbbVie unveiled post‑hoc results from its Phase III TEMPO‑1 and TEMPO‑2 trials of tavapadon, a once‑daily oral D1/D5 partial agonist for early Parkinson’s disease. The analysis showed statistically significant improvements in seven of...
AAN 2026: Head-to-Head Trial Shows Superiority of Qulipta for Migraine Prevention
AbbVie presented Phase IIIb TEMPLE trial data at AAN 2026, showing its oral gepant Qulipta outperforms topiramate in migraine prevention. Over 24 weeks, Qulipta had a 12.1% discontinuation rate versus 29.6% for topiramate and achieved a 73.7% responder rate (>50% reduction in...
Biogen Seeks Darzalex Rivalry in China for Multiple Myeloma with Felzartamab Deal
Biogen has secured exclusive rights to TJ Biopharma’s anti‑CD38 antibody felzartamab in Greater China for up to $850 million, including control of a pending biologics licence application for relapsed and refractory multiple myeloma. The drug will be manufactured domestically at TJ...
Regulatory Round-Up: Novartis, Sanofi and Arrowhead Secure CHMP Blessings
The European Committee for Medicinal Products (CHMP) issued positive opinions on three therapies: Sanofi's BTK inhibitor cenrifki for non‑relapsing secondary progressive multiple sclerosis, Arrowhead's siRNA drug redemplo for familial chylomicronemia syndrome, and Novartis' gene‑replacement therapy itvisma for spinal muscular atrophy....
Cardiometabolic Trials: Using Expertise to Turn Complexity Into Robust Results
Nucleus Network’s Minneapolis site has emerged as a benchmark for early‑phase cardiometabolic trials, leveraging AI‑driven recruitment, rigorous PI oversight, and advanced imaging to deliver decision‑grade data. In the Rivus RIV‑HU6‑203 study the team screened 506 candidates, randomised 80 participants and...
Cumberland to Sell Drug Portfolio to Apotex for $100m
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian generic giant Apotex for $100 million in cash, subject to shareholder approval. The transaction lets Cumberland retain its pipeline assets, including the thromboxane antagonist ifetroban, and its majority...
ESCMID Global 2026: Zelicapavir Demonstrates Benefits for High-Risk Adults with RSV
At ESCMID Global 2026, Enanta Pharmaceuticals presented Phase IIb data for zelicapavir, an oral once‑daily N‑protein inhibitor, in high‑risk adults with RSV. The double‑blind study of 186 participants missed the primary endpoint but demonstrated faster symptom resolution—up to 7 days quicker in...
Pharma Meets AI Conference 2026: Key Barriers to Scaling AI in Drug Development
At the Pharma Meets AI conference in Barcelona, industry leaders warned that trust and governance are the biggest obstacles to scaling artificial intelligence in drug development. While AI is delivering gains in prediction, personalization and productivity, concerns over data quality,...
ESCMID Global 2026: Adibelivir Emerges as Potential Disease-Modifying Therapy for HSV
Innovative Molecules presented Phase I/Ib data on adibelivir (IM‑250), a novel helicase‑primase inhibitor, at ESCMID Global 2026. The drug demonstrated nanomolar potency against clinical and acyclovir‑resistant HSV‑1/2 isolates and showed a favorable safety profile up to 200 mg with no dose‑limiting toxicities....